Rapport Therapeutics, Inc. RAPP
Set alert
25.33 USD +0.20 +0.80%
As of Nov 3, 1:23 PM ET
25.13 Day range 26.06
22.06 52-week range 52.93
- YTD
- -16.51%
- 1 year
- -5.98%
- Open
- 25.39
- Prev close
- 25.13
- Mkt cap
- 1.46B
- Vol
- 272.99K
- Avg vol
- 712.76K
- EPS
- -3.03
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 25.13
- High
- 26.06
- Forward P/E
- -4.94
- Beta
- 1.40
- Short ratio
- 6.70
- Inst. own
- 96.71%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 36.70
- 200-d avg
- 35.65
- 1y target
- 68.29
1M chart
Events in this range
- Oct 15, 2026Rating: UBS · — → Buy
- Oct 20, 2026Rating: BTIG · Buy → Buy
- Oct 20, 2026Rating: HC Wainwright & Co. · Buy → Buy
- Oct 21, 2026Rating: Guggenheim · Buy → Buy
- Oct 21, 2026Rating: Wells Fargo · Overweight → Overweight
- Oct 21, 2026Rating: Jones Trading · Buy → Buy
Signals (7)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | Nov 3, 2026 | 3 hours ago |
| SMA: Bearish | Oct 28, 2026 | 6 days ago |
| RSI: Oversold | Oct 28, 2026 | 6 days ago |
| SMA: Bullish | Oct 27, 2026 | 1 week ago |
| RSI: Oversold | Oct 26, 2026 | 1 week ago |
| RSI: Oversold | Oct 21, 2026 | 1 week ago |
| MACD: Buy Signal | Oct 19, 2026 | 2 weeks ago |
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 68.29 +169.6% upside
Now 25.33
- Target (low)
- 50.00
- Target (mean)
- 68.29
- Target (high)
- 91.00
Ratings (0m) 16 16 buy · 0 hold · 0 sell
- Strong buy1
- Buy15
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 16
- 1 month ago 13
- 2 months ago 13
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -1.22 | -1.36 – -1.08 | -0.71 | -72.1% | 0 | 0.0% | 12 |
| Next quarter | -1.20 | -1.54 – -0.81 | -0.72 | -66.2% | 66.67K | 0.0% | 12 |
| Current year | -4.04 | -4.51 – -3.50 | -2.86 | -41.2% | 20.06M | 0.0% | 12 |
| Next year | -5.09 | -6.80 – -3.81 | -4.04 | -26.0% | 0 | -100.0% | 12 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 21, 2026 | Jones Trading | Maintained | Buy | Buy |
| Oct 21, 2026 | Wells Fargo | Maintained | Overweight | Overweight |
| Oct 21, 2026 | Guggenheim | Maintained | Buy | Buy |
| Oct 20, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Oct 20, 2026 | BTIG | Maintained | Buy | Buy |
| Oct 15, 2026 | UBS | Initiated | — | Buy |
| Oct 15, 2026 | Wolfe Research | Initiated | — | Outperform |
| Oct 6, 2026 | Guggenheim | Initiated | — | Buy |
| Sep 16, 2026 | BTIG | Maintained | Buy | Buy |
| Aug 19, 2026 | BTIG | Reiterated | Buy | Buy |
| Aug 12, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Aug 5, 2026 | BTIG | Reiterated | Buy | Buy |
| Jul 16, 2026 | BTIG | Reiterated | Buy | Buy |
| Jun 24, 2026 | Leerink Partners | Initiated | — | Outperform |
| May 21, 2026 | BTIG | Maintained | Buy | Buy |
| May 8, 2026 | BTIG | Reiterated | Buy | Buy |
| Apr 22, 2026 | BTIG | Reiterated | Buy | Buy |
| Mar 11, 2026 | BTIG | Maintained | Buy | Buy |
| Mar 11, 2026 | Wells Fargo | Maintained | Overweight | Overweight |
| Feb 2, 2026 | Wells Fargo | Initiated | — | Overweight |
| Dec 9, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Dec 8, 2025 | BTIG | Reiterated | Buy | Buy |
| Nov 19, 2025 | BTIG | Initiated | — | Buy |
| Nov 7, 2025 | Citizens | Maintained | Market Outperform | Market Outperform |
| Sep 16, 2025 | Truist Securities | Initiated | — | Buy |
| Sep 8, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Aug 6, 2025 | HC Wainwright & Co. | Initiated | — | Buy |
| Jul 8, 2025 | JMP Securities | Reiterated | Market Outperform | Market Outperform |
| Apr 8, 2025 | JMP Securities | Initiated | — | Market Outperform |
| Oct 18, 2024 | Jones Trading | Initiated | — | Buy |